Products for Research Use Only
RegisterLogin

Semaglutide-d8

CAT: 0804-HY-114118SSize: 100 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114118SSize:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Semaglutide-d8 is the deuterium labeled Semaglutide. Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer[1][2][3][4][5].
UNSPSC
12352209
Target
Apoptosis; Autophagy; Bcl-2 Family; GLP Receptor; Insulin Receptor; Isotope-Labeled Compounds; p38 MAPK; α-synuclein
Related Pathways
Apoptosis; Autophagy; GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; Others; Protein Tyrosine Kinase/RTK
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease; Neurological Disease
Smiles
O=C(O)CNC([C@H](CCCNC(N)=N)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CCC(O)=O)NC([C@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC4=CC=C(O)C=C4)NC([C@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@@H](CO)NC([C@H]([C@H](O)C)NC([C@@](C([2H])([2H])C5=C([2H])C([2H])=C([2H])C([2H])=C5[2H])([2H])NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(C(C)(C)NC([C@H](CC6=CNC=N6)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C187H283D8N45O59
Molecular Weight
4121.63
References & Citations
[1]Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239. |[2]Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017. |[3]Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151 (3) :103. |[4]Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9 (1) :157-171. |[5]Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25 (5) :2961.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-114118-01Semaglutide
HY-114118B-01Semaglutide (acetate)
HY-114118CP-01Semaglutide (crude)
HY-114118A-01Semaglutide (TFA)
HY-114118F-01Semaglutide, FITC labeled
HY-114118S3-01Semaglutide-13C6,15N (TFA)
HY-Z11724-01Semaglutide Main Chain (9-37)
HY-15440ASFostemsavir-d8
HY-W778649-01Sarmentine-d8
HY-W749483Iprovalicarb-d8

Alternative Products

CatalogName
AR-S09591-01Semaglutide-d8
CS-O-43363Semaglutide-d8 Tetratrifluoroacetate
AR-S11197-01Semaglutide-d8 (TFA Salt)
GW8695-25mgSemaglutide

Popular Products